Brickell Biotech (BBI) Peer Comparison

$1.73

$0.00 (0.00%)

As on 09-Nov-2022 09:30EDT

Market cap

$7 Mln

Revenue (TTM)

$5 Mln

P/E Ratio

--

P/B Ratio

0.4

Div. Yield

0 %

Edit

	Brickell Biotech (BBI)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	7	16,765	13,492	11,994	11,957
Revenue ($ Mln)	5	2,782	2,436	670	1,664
Net Profit ($ Mln)	-29.89	491.50	860.62	-319.95	413.60
Net Margin (%)	-643.70	17.67	35.33	-47.79	24.86
RoE (%)	-147.43	110.09	42.98	-71.14	430.03
Price to Earnings	--	35.25	17.40	--	30.89
Price-To-Book	0.41	39.29	7.42	26.87	84.52

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Brickell Biotech (BBI)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Operating Revenue	4.64	1,142.38	1,434.97	138.29	443.31
Cost of Revenue	0.00	814.22	52.87	--	81.41
Gross Profit	0.40	328.16	1,382.10	138.29	361.90
Operating Expenses	35.17	129.54	1,095.43	287.32	86.00
Operating Profit (EBIT)	-29.97	198.62	286.67	-149.04	275.90
Other Income	0.00	3.34	-0.18	2.07	-19.86
Profit before Tax	-29.88	201.85	294.15	-140.85	248.52
Provision for Tax	0.12	20.00	63.09	0.00	-154.19
Profit after Tax (Net Income)	-29.89	181.85	231.06	-140.85	402.71
Minority Interest	0.00	--	--	--	--
Consolidated Profit	-29.88	181.85	231.06	-140.85	402.71

Liabilities ($ Mln)

	Brickell Biotech (BBI)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Shareholder's Funds	15.64	952.93	2,210.62	408.82	196.95
Minority Interest	0.00	--	--	--	--
Non-Current Liabilities	1.30	149.79	68.03	154.79	790.33
Current Liabilities	2.87	557.22	337.59	146.54	117.15
Total Liabilities	29.72	1,659.94	2,616.24	710.15	1,104.43

Assets ($ Mln)

	Brickell Biotech (BBI)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Non-Current Assets	0.26	969.02	781.49	325.55	178.14
Current Assets	18.25	690.91	1,834.75	384.60	926.29
Total Assets	29.72	1,659.94	2,616.24	710.15	1,104.43
Total Debt*	0.04	130.97	51.27	25.55	876.67
Net Current Assets	15.38	133.70	1,497.16	238.06	809.14

Cashflow ($ Mln)

	Brickell Biotech (BBI)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-36.15	263.33	400.80	171.31	299.44
Cash Flow from Investing Activities	-0.04	-31.36	-42.88	-141.68	-406.29
Cash from Financing Activities	32.95	-44.45	-14.80	11.31	77.87
Net Cash Inflow / Outflow	--	187.51	52.64	40.85	-28.98

Ratios

Profitability Ratios

	Brickell Biotech (BBI)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
ROCE (%)	-150.29	18.14	11.03	-30.71	49.66
ROE (%)	-147.43	20.68	11.30	-32.36	231.44
ROA (%)	-104.62	11.92	9.72	-22.85	47.82
EBIT Margin (%)	-643.25	--	--	--	--
Net Margin (%)	-643.70	15.87	16.10	-100.35	95.10
Cash Profit Margin (%)	-0.02	--	--	--	--

Growth Ratios

	Brickell Biotech (BBI)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	1,277.74	0.23	0.45	0.57	0.66
EBIT Growth (%)	6.03	--	--	--	--
Net Profit Growth (%)	6.15	25.08	106.71	-66.58	211.97
EPS Growth (%)	--	0.25	1.04	-0.64	2.14
Book Value Growth (%)	--	--	--	--	--

Valuation Ratios

	Brickell Biotech (BBI)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Price / Earnings	--	45.17	25.57	-46.33	14.40
Price / Book Value	--	8.62	2.67	15.96	29.45
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	0.68	35.34	14.96	-46.64	21.28
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Brickell Biotech (BBI)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Debt to Equity	0.00	0.14	0.02	0.06	4.45
Short term debt to equity ratio	0.00	0.17	0.00	0.01	0.45
Current Ratio	6.36	1.24	5.43	2.62	7.91
Quick Ratio	6.36	--	5.35	2.59	7.45
Interest Coverage	-2,715.09	1,923.40	--	-23.01	36.66

Operating Efficiency Ratios

	Brickell Biotech (BBI)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	10.98	16.32	19.70	7.42	20.52
Asset Turnover	0.16	0.75	0.60	0.22	0.53
Receivable days	--	55.54	56.45	14.66	77.74
Inventory Days	--	0.00	167.40	--	257.19
Payable days	--	11.71	165.41	--	7.78
Cash Conversion Cycle	--	48.64	58.44	--	327.15

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly